Alpaca

Alpaca Adverse Event Insights

The FDA Center for Veterinary Medicine database holds 33 adverse event reports for Alpaca, distributed across 1 distinct breeds currently tracked in the system. Of those reports, 9 involved a death outcome — producing a 2730.0% case-fatality rate among reported events, which reflects reporting severity bias rather than true population mortality. These figures are aggregated directly from openFDA's Animal & Veterinary Adverse Events endpoint and update as new voluntary submissions flow through pet owners, veterinarians, and drug manufacturers.

The most frequently reported clinical signs for Alpaca are Death (7 reports), Diarrhoea (3 reports), Ataxia (3 reports), Injection site swelling (2 reports), with Death leading the reaction traffic at 7 submissions. On the product side, Ivermectin is the single most-referenced drug with 3 reports, followed by Fenbendazole (3), Tulathromycin (2), Fentanyl (2). This combination surfaces which therapeutic classes generate the most adverse event chatter for this species — a useful starting point when comparing Alpaca reporting patterns against other companion animals in the dataset.

Of the 32 Alpaca reports with a coded outcome, Recovered/Normal accounts for the largest share at 37.5%. Annual submission volume spans 2,010 to 2,023 reports across the 12 years on file, a range that reflects evolving owner awareness, veterinary reporting habits, and new product approvals rather than stable underlying incidence. The breed-level table below breaks these patterns down further, showing how the 1 tracked alpaca breeds compare on volume, deaths, and average age at report. As with all FDA adverse event data, correlation is the ceiling — causation requires clinical investigation beyond what these aggregates can provide.